Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: Haolin Ni who wrote (870)	1/23/1998 5:57:00 PM
From: David S.	Read Replies (2) \| Respond to of 3579

if this company goes bust, I promise to walk your dog every day of the week for a year. If it doesn't what will you do for me?

To: Haolin Ni who wrote (870)	1/23/1998 7:19:00 PM
From: BulbaMan	Read Replies (1) \| Respond to of 3579

>>You will see whether there is new revenue come from Boehringer in next Q 10Q.<< So, you admit that you have no way of knowing whether Geron got a payment from Boehringer until they release 1997 Q4 results. With about $25 million in cash and a $2 million quarterly burn rate, this gives Geron about 3 years of cash. A 3 year cash position is generally considered very good for biotechs in Geron's category. Also, Geron should be getting milestone payments from Pharmacia & Upjohn over the next few years and I'm confident they will be partnering with other companies on telomerase in the near future. Personally, I think you're completely off-the-wall about the company profile being being a ploy by Geron to "prop up" its price. Such profiles periodically appear on the Yahoo news list for various companies and my understanding is they're released as a service by BusinessWire.